Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Boers

Showing results (31-40 of 123) with videos related to

Pageof 13
Sort By:
Nature Genetics|May 1, 1995
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseP Frosst, H J Blom, R Milos, et al.
The Netherlands Journal of Medicine|September 16, 2004
A clinical and cardiovascular survey of Ehlers-Danlos syndrome patients with complete deficiency of tenascin-XA C T M Peeters, M Kucharekova, J Timmermans, et al.
Targeted Oncology|March 1, 2014
Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CTMarye J Boers-Sonderen, Lioe-Fee de Geus-Oei, Ingrid M E Desar, et al.
British Journal of Cancer|December 25, 2013
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I studyP Hamberg, M J Boers-Sonderen, W T A van der Graaf, et al.
Rheumatology (Oxford, England)|June 6, 2002
Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritisA E van Ede, R F J M Laan, H J Blom, et al.
Cancers|August 7, 2021
Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV MelanomaSofie H Tolmeijer, Rutger H T Koornstra, Jan Willem B de Groot, et al.
Acta Oncologica (Stockholm, Sweden)|March 10, 2016
Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?Marye J Boers-Sonderen, Sasja F Mulder, Iris D Nagtegaal, et al.
European Urology|September 18, 2012
Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinomaAlexander B Stillebroer, Otto C Boerman, Ingrid M E Desar, et al.
Anticancer Research|September 27, 2015
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell CancerMarye J Boers-Sonderen, Ingrid M E Desar, Jurgen J Fütterer, et al.
Cancer Chemotherapy and Pharmacology|June 27, 2014
Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)Marye J Boers-Sonderen, Carla M L van Herpen, Winette T A van der Graaf, et al.
Pageof 13

Showing results (31-40 of 123) with videos related to

Sort By:
Pageof 13
Nature Genetics|May 1, 1995
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseP Frosst, H J Blom, R Milos, et al.
The Netherlands Journal of Medicine|September 16, 2004
A clinical and cardiovascular survey of Ehlers-Danlos syndrome patients with complete deficiency of tenascin-XA C T M Peeters, M Kucharekova, J Timmermans, et al.
Targeted Oncology|March 1, 2014
Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CTMarye J Boers-Sonderen, Lioe-Fee de Geus-Oei, Ingrid M E Desar, et al.
British Journal of Cancer|December 25, 2013
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I studyP Hamberg, M J Boers-Sonderen, W T A van der Graaf, et al.
Rheumatology (Oxford, England)|June 6, 2002
Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritisA E van Ede, R F J M Laan, H J Blom, et al.
Cancers|August 7, 2021
Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV MelanomaSofie H Tolmeijer, Rutger H T Koornstra, Jan Willem B de Groot, et al.
Acta Oncologica (Stockholm, Sweden)|March 10, 2016
Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?Marye J Boers-Sonderen, Sasja F Mulder, Iris D Nagtegaal, et al.
European Urology|September 18, 2012
Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinomaAlexander B Stillebroer, Otto C Boerman, Ingrid M E Desar, et al.
Anticancer Research|September 27, 2015
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell CancerMarye J Boers-Sonderen, Ingrid M E Desar, Jurgen J Fütterer, et al.
Cancer Chemotherapy and Pharmacology|June 27, 2014
Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)Marye J Boers-Sonderen, Carla M L van Herpen, Winette T A van der Graaf, et al.
Pageof 13